In conclusion, the regulation of the NF-κB pathway by fingolimod and its effects on immune cell migration and astrocyte activation render it a promising therapeutic option for MS, potentially attenuating disease progression and protecting against neurodegeneration. Here, NFKB1 is linked to myeloid sarcoma.